Who are Antithymocyte globulin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): tacrolimus, ATG, ATG, Anti-Thymocyte Globulins treatment, rabbit anti-thymocyte globulin - 4 doses.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/antithymocyte-globulin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-09 · How we verify

Antithymocyte globulin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Antithymocyte globulin (Antithymocyte globulin) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Polyclonal antithymocyte antibody. Area: Immunology.

marketed Polyclonal antithymocyte antibody Multiple T-cell surface antigens (CD2, CD3, CD4, CD8, HLA-DR) Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Antithymocyte globulin (Antithymocyte globulin) — National Institute of Allergy and Infectious Diseases (NIAID). Antithymocyte globulin (ATG) is a polyclonal antibody preparation that depletes T lymphocytes by binding to and eliminating T cells in the circulation and lymphoid tissues.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Antithymocyte globulin TARGET	Antithymocyte globulin	National Institute of Allergy and Infectious Diseases (NIAID)	marketed	Polyclonal antithymocyte antibody	Multiple T-cell surface antigens (CD2, CD3, CD4, CD8, HLA-DR)
tacrolimus, ATG	tacrolimus, ATG	University Hospital, Toulouse	marketed	Calcineurin inhibitor and polyclonal antithymocyte antibody	Calcineurin (tacrolimus); T-cell surface antigens including CD2, CD3, CD4, CD8, CD25 (ATG)
ATG	ATG	ITB-Med LLC	marketed	Polyclonal antithymocyte antibody	T-cell surface antigens (CD2, CD3, CD4, CD8, and other T-cell markers)
Anti-Thymocyte Globulins treatment	Anti-Thymocyte Globulins treatment	Nantes University Hospital	marketed	Polyclonal antithymocyte antibody	T-cell surface antigens (CD2, CD3, CD4, CD8, HLA-DR)
rabbit anti-thymocyte globulin - 4 doses	rabbit anti-thymocyte globulin - 4 doses	University of Nebraska	marketed	Polyclonal antithymocyte antibody	T lymphocyte surface antigens (CD2, CD3, CD4, CD8, HLA-DR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Polyclonal antithymocyte antibody class)

ITB-Med LLC · 1 drug in this class
Nantes University Hospital · 1 drug in this class
National Institute of Allergy and Infectious Diseases (NIAID) · 1 drug in this class
University of Nebraska · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Antithymocyte globulin — Competitive Intelligence Brief. https://druglandscape.com/ci/antithymocyte-globulin. Accessed 2026-06-09.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing